Unity Biotechnology, Inc. (0YC0.L)
USD 1.02
(-1.45%)
USD 1.02
(-1.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -19.69 Million USD | -913.32% |
| 2022 | -1.94 Million USD | -202.1% |
| 2021 | 1.9 Million USD | 155.2% |
| 2020 | -3.44 Million USD | -29.52% |
| 2019 | -2.66 Million USD | -22.16% |
| 2018 | -2.18 Million USD | 93.94% |
| 2017 | -35.99 Million USD | -23423.53% |
| 2016 | -153 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -227 Thousand USD | -113.58% |
| 2024 Q2 | -221 Thousand USD | 2.64% |
| 2024 Q3 | -216 Thousand USD | 2.26% |
| 2023 Q2 | -314 Thousand USD | 4.56% |
| 2023 Q4 | 1.67 Million USD | 642.53% |
| 2023 FY | -1.18 Million USD | 39.2% |
| 2023 Q1 | -329 Thousand USD | 48.99% |
| 2023 Q3 | -308 Thousand USD | 1.91% |
| 2022 Q4 | -645 Thousand USD | -20.56% |
| 2022 Q3 | -535 Thousand USD | -43.43% |
| 2022 FY | -1.94 Million USD | -202.1% |
| 2022 Q2 | -373 Thousand USD | 40.51% |
| 2022 Q1 | -627 Thousand USD | -13106287.29% |
| 2021 Q1 | -757 Thousand USD | 98.85% |
| 2021 FY | 1.9 Million USD | 155.2% |
| 2021 Q4 | 4.78 USD | 100.0% |
| 2021 Q3 | -708 Thousand USD | 4.84% |
| 2021 Q2 | -744 Thousand USD | 1.72% |
| 2020 Q1 | - USD | -100.0% |
| 2020 FY | -3.44 Million USD | -29.52% |
| 2020 Q4 | -65.8 Million USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q3 | -17.77 Million USD | 3.74% |
| 2019 Q1 | -16.5 Million USD | -1.07% |
| 2019 FY | -2.66 Million USD | -22.16% |
| 2019 Q4 | 52.75 Million USD | 396.73% |
| 2019 Q2 | -18.46 Million USD | -11.89% |
| 2018 Q2 | -15.19 Million USD | -16.68% |
| 2018 FY | -2.18 Million USD | 93.94% |
| 2018 Q1 | -13.02 Million USD | -27.58% |
| 2018 Q4 | -16.32 Million USD | -13.77% |
| 2018 Q3 | -14.35 Million USD | 5.56% |
| 2017 Q2 | -9.21 Million USD | -32.18% |
| 2017 FY | -35.99 Million USD | -23423.53% |
| 2017 Q1 | -6.97 Million USD | 0.0% |
| 2017 Q4 | -10.2 Million USD | -6.35% |
| 2017 Q3 | -9.59 Million USD | -4.19% |
| 2016 FY | -153 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 80.208% |
| Dynavax Technologies Corporation | 182.11 Million USD | 110.817% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 103.761% |
| Perrigo Company plc | 1.68 Billion USD | 101.172% |
| Illumina, Inc. | 2.74 Billion USD | 100.718% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.129% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -105.927% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.074% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.376% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 296.166% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.174% |
| Waters Corporation | 1.76 Billion USD | 101.119% |
| Biogen Inc. | 7.3 Billion USD | 100.27% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 56.538% |
| Evolus, Inc. | 140.52 Million USD | 114.018% |
| Adicet Bio, Inc. | -6.09 Million USD | -223.04% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 233.155% |
| bluebird bio, Inc. | -4.03 Million USD | -388.809% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 126.96% |
| FibroGen, Inc. | 128.9 Million USD | 115.282% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.569% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 36.797% |
| Homology Medicines, Inc. | -7.22 Million USD | -172.5% |
| Geron Corporation | -123.5 Million USD | 84.05% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 101.298% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 105.441% |
| Myriad Genetics, Inc. | 476.4 Million USD | 104.135% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -6646.233% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 95.06% |
| Zoetis Inc. | 5.83 Billion USD | 100.338% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 6622.848% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.908% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 101.034% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.229% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -6401.32% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 102.53% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -6193.61% |
| Verastem, Inc. | -62 Thousand USD | -31672.581% |
| Nektar Therapeutics | 53.47 Million USD | 136.836% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 108.056% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 76.883% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 101.802% |
| OPKO Health, Inc. | 318.12 Million USD | 106.192% |
| Exelixis, Inc. | 1.75 Billion USD | 101.121% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 101.066% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 104.139% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| uniQure N.V. | 2.21 Million USD | 989.345% |
| Imunon, Inc. | -720 Thousand USD | -2635.953% |
| Blueprint Medicines Corporation | 236.58 Million USD | 108.326% |
| Insmed Incorporated | 239.63 Million USD | 108.22% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 103.093% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 213.742% |
| TG Therapeutics, Inc. | 219.1 Million USD | 108.991% |
| Incyte Corporation | 3.44 Billion USD | 100.573% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 105.728% |